In Japan, HTA is systematically used to determine whether a new technology should be covered and also to determine the reimbursement level or the reimbursement price of technologies. Cost-benefit evaluation has tentatively introduced since 2016, to be used for price adjustment of pharmaceuticals and medical devices. The circumstances which HTA applied will be considered for the full-introduction.